Perspective Therapeutics, Inc. cotiza a 2.27 USD y tiene una capitalización bursátil de $259M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or met…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.22 | $-0.25 | $-0.51 |
| Estimado | $-0.25 | $-0.27 | $-0.32 | $-0.34 |
| Sorpresa | — | +18.5% | +21.9% | -50.0% |
| Métrica | CATX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -12846.6% | -38.6% | -12808.0% |
| Net Margin | -11665.3% | -33.6% | -11631.7% |
| FCF Margin | -10773.0% | -13.9% | -10759.1% |
| ROE | -49.8% | -40.4% | -9.4% |
| ROA | -38.6% | -32.0% | -6.6% |
| Current Ratio | 5.17 | 2.84 | +2.33 |
| Debt / Equity | 0.01 | 0.28 | -0.27 |